Video

Dr. Lowentritt discusses findings from phase 3 ARASENS trial in mHSPC

“I do think that this helps inform how to choose an agent for this specific stage of the disease,” says Benjamin Lowentritt, MD, FACS.

Video Player is loading.
Current Time 0:00
Duration 2:49
Loaded: 5.81%
Stream Type LIVE
Remaining Time 2:49
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    In this video, Benjamin Lowentritt, MD, FACS, shares his thoughts on the pivotal study, “Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Lowentritt is the director of minimally invasive surgery and robotics and the director of the Prostate Cancer Care Program at Chesapeake Urology in Baltimore, Maryland.

    © 2025 MJH Life Sciences

    All rights reserved.